Unicycive Therapeutics (UNCY) EBT Margin (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly EBT Margin came in at 34556.59% in Q1 2023, down 5617.35% on a QoQ basis from 604.42% in Q3 2022.
Unicycive Therapeutics (UNCY) EBT Margin (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of EBT Margin data on file, last reported at 34556.59% in Q1 2023.
- Quarterly EBT Margin changed N/A year-over-year to 34556.59% in Q1 2023, while the trailing twelve-month figure through Dec 2023 was 57386.52% (changed N/A YoY) and the FY2023 annual result came in at 4642.22%, down 196189.0% from the prior year.
- EBT Margin retreated to 34556.59% in Q1 2023, from 604.42% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 604.42% in Q3 2022 to a low of 34556.59% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 12.09% |
| 10 | Unicycive Therapeutics | 149.66 Mn | 149.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -34,556.59% |
| Sep 30, 2022 | -604.42% |